Drugs / VM-1500A-LAI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05204394 | Apr 2022 → Sep 2023 | HIV infectious disease | Viriom | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-07-08 | ChemRar Research and Development Institute, LLC | Компания «Вириом» представила результаты исследований VM-1500A-LAI на международной конференции по ВИЧ в Гонконге chemrar.ru ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VM-1500A-LAI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05204394 ↗ |
| Route | Intramuscular | “one IM injection of 1200 mg VM-1500A-LAI followed by 5 IM monthly injections of 600 mg or 900 mg VM-1500A-LAI QM” NCT05204394 ↗ |